Research Focus: Emerging Insights Into Therapeutic Strategies for Relapsed and Refractory Hairy Cell Leukemia
Learning Module - In this CME-certified activity, Farhad Ravandi, MD, explores optimal current treatment of this rare leukemia, including standard systemic therapies and targeted approaches, as well as emerging therapies. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - April 18, 2018 Category: Hematology Source Type: research
Research Focus: Emerging Insights Into Therapeutic Strategies for Relapsed and Refractory Hairy Cell Leukemia
Slideset - In this downloadable slideset from the CME-certified hairy cell leukemia activity, Farhad Ravandi, MD, provides expert perspective on selecting optimal treatment strategies and promising therapies for your patients with HCL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - April 18, 2018 Category: Hematology Source Type: research
ASH 2017: Advances in the Treatment of Acute and Chronic Leukemias
Learning Module - In this expert analysis, Farhad Ravandi, MD, and B. Douglas Smith, MD, review the clinically relevant studies on the management of acute and chronic leukemias presented at the Hematology 2017 annual meeting. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - February 23, 2018 Category: Hematology Source Type: research
GIMEMA LAL1811: Phase II Study of Frontline Ponatinib + Steroids in Elderly or Unfit Patients With Ph+ ALL
Slideset - Ponatinib combined with steroids yielded a 90% complete hematologic response and reasonable tolerability profile at Week 24 in unfit and elderly patients with Philadelphia chromosome –positive ALL. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 20, 2017 Category: Hematology Source Type: research
Phase I Study: Ivosidenib (AG-120) in Mutant < i > IDH1 < /i > Acute Myeloid Leukemia and Other Advanced Hematologic Malignancies
Slideset - Ivosidenib, an investigational mutantIDH1 inhibitor, was well tolerated with evidence of activity and durable responses in patients with malignancies harboring mutatedIDH1. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 20, 2017 Category: Hematology Source Type: research
Phase III PETALs Interim Analysis: Nilotinib ± PegIFN alfa-2a in Patients With Newly Diagnosed Ph-Positive CP CML
Slideset - Combining peginterferon-alfa 2a with nilotinib in patients with chronic-phase CML showed significantly better rates of deep molecular response than nilotinib alone. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 19, 2017 Category: Hematology Source Type: research
Phase II Study: Frontline Cytarabine and Idarubicin + Nivolumab in Newly Diagnosed AML
Slideset - Study reported median event-free survival of 8.3 months in patients receiving nivolumab plus cytarabine and idarubicin with manageable safety profile. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 19, 2017 Category: Hematology Source Type: research
Phase III HOVON97: Azacitidine Maintenance in Older Patients With AML and Refractory Anemia
Slideset - Azacitidine was well tolerated and significantly improved disease-free survival in older patients with anemia-refractory AML. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 18, 2017 Category: Hematology Source Type: research
Phase I/II Study of Venetoclax + Low-Dose Cytarabine in Untreated, Elderly Patients With AML: Outcomes at 1 Year
Slideset - After more than 1 year of follow-up, the combination of venetoclax plus low-dose cytarabine achieved a CR + CRi rate of 62% and a median OS of 11.4 months in elderly patients with AML who are unfit for chemotherapy. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 18, 2017 Category: Hematology Source Type: research
CPX-351 in Patients With Newly Diagnosed AML at High Risk for Induction Mortality: Initial Phase II Results
Slideset - Preliminary findings demonstrate that the CPX-351 liposomal formulation of cytarabine:daunorubicin is both safe and active at reduced and higher doses in patients with AML at high risk for death during induction chemotherapy. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 18, 2017 Category: Hematology Source Type: research
Phase I Study: Ivosidenib or Enasidenib + Standard Induction Chemotherapy in Newly Diagnosed AML With < i > IDH1/IDH2 < /i > Mutations
Slideset - The combination of IDH inhibitors enasidenib or ivosidenib with standard 7 + 3 induction chemotherapy appears safe with response rates comparable to those expected with standard induction chemotherapy in patients with either de novo or secondary AML. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 15, 2017 Category: Hematology Source Type: research
Prospective Molecular MRD Detection in AML by Next-Generation Sequencing
Slideset - This large prospective study shows that identification of residual leukemia by targeted next-generation sequencing of select mutations present in CR serves as a strong independent predictor for AML relapse and survival. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 14, 2017 Category: Hematology Source Type: research
Prognostic Role of < i > NPM1/FLT3 < /i > -ITD Genotypes in AML: Analysis of the RATIFY Trial
Slideset - Results confirm strong prognostic value ofNPM1/FLT3-ITD genotypes in AML, supporting 2017 ELN risk stratification criteria that includeFLT3-ITD allelic burden. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 14, 2017 Category: Hematology Source Type: research
Gilteritinib With Induction and Consolidation Chemotherapy for Newly Diagnosed AML: Preliminary Phase I Results
Slideset - Preliminary data suggest novel combination of gilteritinib and chemotherapy has antileukemic effect inFTL3-mutated AML with acceptable safety. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 13, 2017 Category: Hematology Source Type: research
Integrating Emerging Targeted Therapies Into AML Treatment Strategies
Slideset - In this downloadable slideset, Roland B. Walter, MD, PhD, MS, examines FLT3, IDH1, and BCL2 inhibitors as well as other promising investigational treatments in clinical trial that may provide therapeutic advances for the management of patients with acute myeloid leukemia. (Source: Clinical Care Options Leukemia)
Source: Clinical Care Options Leukemia - December 13, 2017 Category: Hematology Source Type: research
